A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

Inclusion Criteria: 1. Healthy male or female volunteer, ages 18-to-55 years, inclusive. 2. BMI must be between 18 and 32 kg/m2 (inclusive) and weigh a minimum of 50 kg (110 lbs). BMI is calculated as weight in kg divided by the square of height measured in meters. 3. A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG). 4. If female, be postmenopausal (at least 2 years prior to dosing), surgically sterile (6 months post tubal ligation), or agree to use an acceptable form of birth control from screening until 28 days after dosing. Subjects who claim postmenopausal status will have status confirmed with a follicle-stimulating hormone (FSH) test. Acceptable forms of birth control for females include the following: * Vasectomized partner (at least 6 months prior to dosing) * Surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) at least 6 months prior to dosing * Non-surgical permanent sterilization (eg, Essure procedure) at least 3 months prior to dosing * Double barrier (diaphragm with spermicide; condoms with spermicide) * Nonhormonal intrauterine device * Abstinence (must agree to use a double barrier method if they become sexually active during the study) 5. If male, agree to use an acceptable method of birth control during the study and in the 90 days following dosing. Acceptable forms of birth control for males include the following: * Vasectomy (at least 6 months before dosing) * Partner is surgically sterilized (see methods above for females) * Partner uses oral, injectable, or implantable hormonal contraceptives or intrauterine device (IUD) * Double barrier (partner uses diaphragm with spermicide; condoms with spermicide) * Abstinence (subject must agree to use a double barrier method if subject becomes sexually active during the study) 6. If female, agree to not breastfeed or donate ova from the time of consenting to the study and for 28 days after dosing the study drug. 7. If male, agree to not donate sperm from the time of consenting to the study and for 90 days after dosing the study drug. 8. Be able to verbalize an understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English. 9. Complete all assessments required at screening and baseline and be available to stay in t…